Stockscreener 앱 받기
130.98
0.99%
1.28
시간 외 거래:
131.83
0.85
+0.65%
전일 마감가:
$129.70
열려 있는:
$130.375
하루 거래량:
10.46M
Relative Volume:
1.47
시가총액:
$221.92B
수익:
$41.95B
순이익/손실:
$13.40B
주가수익비율:
17.12
EPS:
7.65
순현금흐름:
$6.35B
1주 성능:
+5.20%
1개월 성능:
+2.62%
6개월 성능:
+11.10%
1년 성능:
+23.68%
1일 변동 폭
$129.66
$132.71
1주일 범위
$124.04
$134.16
52주 변동 폭
$99.71
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott expects a ‘few hundred million’ in tariff costs in 2025 - Manufacturing Dive
Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call Transcript - MSN
Brazil Enteral Nutrition Market Overall Study Report 2025-2032 - openPR.com
Tariff-Resistant Abbott Laboratories on Track for New Highs - Investing.com
Tariff-Resistant Abbott Laboratories on Track for New Highs - Investing.com
Abbott Laboratories’ Earnings Call Highlights Robust Growth - TipRanks
Abbott Laboratories Plans $500M Manufacturing, R&D Expansion In DFW and Chicago - Bisnow
Abbott Laboratories Adjusts Financial Outlook With Increased Price Target - Evrim Ağacı
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
RBC Capital lifts Abbott Labs target to $145, maintains Outperform By Investing.com - Investing.com India
Abbott Labs stock target raised to $144 by Bernstein SocGen - Investing.com India
RBC Capital lifts Abbott Labs target to $145, maintains Outperform - Investing.com
UBS maintains Buy on Abbott Labs with $148 price target By Investing.com - Investing.com India
Abbott price target raised to $140 from $138 at Evercore ISI - Yahoo Finance
Abbott Labs (ABT) Stock: Earnings Beat with Strong MedTech Growth and $500M U.S. Investment - CoinCentral
UBS maintains Buy on Abbott Labs with $148 price target - Investing.com
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings - Benzinga
Piper Sandler raises Abbott Labs target to $145, keeps Overweight By Investing.com - Investing.com India
Piper Sandler raises Abbott Labs target to $145, keeps Overweight - Investing.com
Citi Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews - Benzinga
RBC Capital Increases Price Target for Abbott (ABT) to $145 | ABT Stock News - GuruFocus
Stifel cuts Abbott Labs stock target to $135, maintains buy rating - Investing.com India
Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating - TipRanks
Oppenheimer Increases Price Target for Abbott (ABT) to $140 | ABT Stock News - GuruFocus
Abbott Laboratories (ABT): Among the Innovative Healthcare Stocks to Watch in 2025 - Yahoo Finance
Bernstein Boosts Abbott (ABT) Price Target to $144 on Strong Performance | ABT Stock News - GuruFocus
BTIG Ups Abbott (ABT) Price Target After Impressive Q1 Earnings | ABT Stock News - GuruFocus
Abbott Laboratories: Strong Growth and Resilience Justify Buy Rating - TipRanks
Oppenheimer lifts Abbott Labs target to $140, maintains outperform By Investing.com - Investing.com India
Oppenheimer lifts Abbott Labs target to $140, maintains outperform - Investing.com
BTIG raises Abbott Labs stock price target to $145 - Investing.com
Raymond James raises Abbott Labs price target to $142 - Investing.com
Raymond James raises Abbott Labs price target to $142 By Investing.com - Investing.com UK
Street View: Abbott's effective management could help it triumph over tariffs - TradingView
Abbott Laboratories (ABT) Q1 2025 Earnings Call Highlights: Strong Growth in Medical Devices ... - Yahoo Finance
Abbott Laboratories (ABT) Q1 2025 Earnings Call Highlights: Strong Growth in Medical Devices and Nutrition Amidst Diagnostics Challenges - GuruFocus
Abbott Laboratories Reports Strong Q1 2025 Results - TipRanks
Abbott to Expand US Manufacturing as Tariffs Loom - MSN
Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential - TipRanks
Is Abbott a Beacon of Hope in the Tariff Conflict? - Medical Device and Diagnostic industry
Wintrust Business Minute: Abbott Laboratories to spend $500 million on manufacturing facilities, including one in Illinois - WGN Radio 720
Stocks Sink After Nvidia Warning: TG Therapeutics, Abbott Labs, Loar In Focus - Investor's Business Daily
Nvidia, AMD, ASML, United, Tesla, Abbott Labs, Travelers, Interactive Brokers, and More Movers - Barron's
Hertz, Abbott Laboratories, and Interactive Brokers: Trending tickers - Yahoo Finance
Health Giant Makes A Bullish Move Despite Mixed Report - Investor's Business Daily
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices (NYSE:ABT) - Seeking Alpha
Is Abbott Laboratories (ABT) the Best Dividend Monarch to Invest in Now? - Insider Monkey
Abbott to invest millions in Irving facility - The Business Journals
Healthcare Stocks Take A Hit Despite Abbott's Earnings Beat - Finimize
Abbott Labs Stock Jumps on Strong Earnings, With $500M Investment in US Facilities - MSN
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.46%
자본화:
|
볼륨(24시간):